Glycated hemoglobin News and Research

RSS

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

Dash diet cuts diabetes complications by targeting blood pressure kidney health and inflammation

The DASH diet supports metabolic health in people with diabetes by improving blood pressure, renal function, lipids, and modest glycemic markers while reducing risks linked to vascular and inflammatory pathways. Its broad nutrient-driven mechanisms also benefit related conditions such as neuropathy, PCOS, and retinopathy, making it a versatile tool for cardiometabolic care.

16 Nov 2025

What diet do people with type 2 diabetes really want? Study reveals flexibility beats strict meal plans

A large UK survey of adults with type 2 diabetes found that most prefer flexible, food-based diets—particularly moderate calorie restriction or low-carbohydrate plans, over formula-based regimens. Preferences varied by age, lifestyle, and desired outcomes, underscoring the need for personalized dietary support.

11 Nov 2025

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

10 Nov 2025

Aligning your body clock may protect your heart and metabolism, says AHA

A new American Heart Association scientific statement highlights how maintaining circadian health through regular sleep, light exposure, meal timing, and exercise may reduce cardiometabolic disease risk. Disrupting these daily rhythms can impair glucose regulation, blood pressure, and cardiovascular function.

29 Oct 2025

Intensive program leads to high type 2 diabetes remission in India

Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort achieved remission through an intensive lifestyle intervention program, according to a new study publishing October 22, 2025, in the open-access journal PLOS One by Pramod Tripathi of Freedom from Diabetes Clinic & Diabetes Research Foundation, India, and colleagues.

23 Oct 2025

Smarter insulin pump systems help stabilize glucose in young patients, study reveals

A Polish study comparing insulin pump technologies in children with type 1 diabetes found that advanced hybrid closed-loop systems achieved superior glycemic stability compared to predictive low glucose suspend systems. Despite technological advances, poor diet and low physical activity still undermine optimal metabolic control.

22 Oct 2025

Home blood tests could spot early heart risks in young adults

Self-administered dried blood spot kits show potential for cardiometabolic screening in young adults, but success relied heavily on clear guidance and researcher support. High rates of at-risk biomarkers highlight an urgent need for early prevention in this population.

12 Oct 2025

Prediabetes can go into remission without weight loss

Research shows up to 22% of prediabetic individuals achieve remission without weight loss, emphasizing metabolic health over weight loss in diabetes prevention.

2 Oct 2025

Myo-inositol fails to lower pregnancy risks in women with PCOS

Myo-inositol supplementation shows no significant benefits in preventing pregnancy complications for women with PCOS, according to a recent large-scale study.

30 Sep 2025

Can a mango a day keep diabetes away?

The study reveals that daily mango consumption may enhance insulin sensitivity and reduce body fat in prediabetic adults, emphasizing whole fruits' advantages.

29 Sep 2025

Precision probiotics lower blood sugar and cholesterol in mice

Researchers developed a precision probiotic cocktail comprising three Lactobacillus strains that improved glucose control, reduced weight gain, and lowered cholesterol levels in mice fed a high-fat diet. Metabolomic and microbiome analyses revealed host metabolic adaptations and beneficial shifts in gut bacteria, highlighting translational potential for future clinical trials.

28 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

AI model maps lifetime disease risks to transform future healthcare planning

Researchers developed Delphi-2M, a transformer-based AI trained on UK Biobank and Danish health data to predict and simulate lifetime trajectories for 1,256 diseases. It accurately forecasted long-term multimorbidity risks, generated synthetic health records, and highlighted comorbidity patterns while exposing key biases.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025